92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks ( EASI -50); 70.4% achieved a 75% reduction in 4 weeks ( EASI -75); 44.4% achieved a 90% reduction in 4 weeks ( EASI -90); and 51.9% achieved a 90% reduction in 8 weeks ( EASI -90) Interim analysis informed
Study demonstrates statistically significant reduction in disease severity in a murine dermatitis model characterized by IL-36 expression First in a planned series of peer-reviewed publications exploring the scientific rationale and non-systemic mechanism underlying GX-03, currently in Phase 2
WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--May 19, 2026-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will present at the
Dr. Hahn Brings Unparalleled Clinical and Regulatory Expertise to Support Advancement of GX-03 for Moderate-to-Severe Atopic Dermatitis and Pipeline Indications WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--May 18, 2026-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company
Phase 2 Trial for GX-03 in Moderate-to-Severe Atopic Dermatitis (AD) on Track, Topline Results Expected Mid-2026 Initial Tranche of $7 Million in Growth Capital has been Funded by Avenue Capital Group WESTLAKE VILLAGE, Calif. --(BUSINESS WIRE)--May 11, 2026-- Turn Therapeutics Inc.
Phase 2 Trial for GX-03 in Moderate-Severe Atopic Dermatitis on Track, Topline Results Expected Mid-2026 Secured up to $25 Million in Growth Capital from Avenue Capital Group Strengthened Leadership Team via Appointments of Dr. Robert Redfield and Martin Dewhurst LOS ANGELES --(BUSINESS WIRE)--Mar.
Financing Extends Runway and Supports Continued Advancement of Atopic Dermatitis (Eczema) and Onychomycosis (Nail Fungus) Programs LOS ANGELES --(BUSINESS WIRE)--Mar. 24, 2026-- Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage dermatology company developing novel therapies for inflammatory
Nationally recognized public health leader and former Director of the CDC to provide strategic guidance on GX-03 development, the Company’s lead investigational therapy LOS ANGELES --(BUSINESS WIRE)--Feb. 17, 2026-- Turn Therapeutics, Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company
LOS ANGELES --(BUSINESS WIRE)--Feb. 9, 2026-- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatology, today announced that Brad Burnam, Chief Executive Officer, will present at the 46th Annual TD Cowen
Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analysis and topline data in first half of 2026 Appointment of Martin Dewhurst , a 30+ years McKinsey & Company M&A veteran, strengthens Company board of directors Expansion of intranasal vaccine pipeline